In line with these findings, our results show that, in our analyzed eight types of tumors, low expression of Neogenin predicts worse patient prognosis (Fig. 1B), and we found that Neogenin has robust efficacy in inhibiting the outgrowth, migration, and invasion of CRC or glioma cells. This evidence concerns the gene NEO1 and glioma.